期刊文献+

汉族急性缺血性脑卒中患者CYP2C19基因多态性与氯吡格雷抵抗的多因素分析 被引量:7

Multivariate analysis of the correlation between the gene ploymorphisms of CYP2C19 and clopidogrel's resistance in Han nationality acute ischemic stroke patients
下载PDF
导出
摘要 目的分析汉族急性缺血性脑卒中患者CYP2C19基因多态性与氯吡格雷抵抗的关系。方法 2012年7月—2014年9月连续性纳入住院并服用氯吡格雷抗血小板聚集治疗(75 mg/d,连续>7 d)的急性缺血性脑卒中患者72例。根据对二磷酸腺苷(ADP)诱导的血小板聚集抑制率将患者分为氯吡格雷抵抗(CR)组(27例)和非抵抗(NCR)组(45例)。基因芯片法检测受试者的CYP2C19基因型,依据突变类型,分为快代谢型(*1/*1)、中间代谢型(*1/*2、*1/*3)和慢代谢型(*2/*2、*2/*3、*3/*3)。采用多元Logistic回归分析筛选与发生氯吡格雷抵抗相关的危险因素。结果 2组CYP2C19基因型的分布比较差异有统计学意义(x^2=32.302,P<0.05);检出CYP2C19基因型为慢代谢型7例(9.7%),中间代谢基因型39例(54.2%),快代谢型26例(36.1%);3组的血小板聚集抑制率分别为(67.5±21.6)%、(57.6±23.4)%和(31.4±15.1)%,慢代谢型>中间代谢型>快代谢型(P<0.01)。多因素Logistic回归分析结果显示CYP2C19慢代谢型(*2/*2、*2/*3)(OR=7.802,95%CI 1.412~40.304,P=0.018)和低密度脂蛋白水平>2.6 mmol/L(OR=3.923,95%CI 1.314~17.927,P=0.032)是发生氯吡格雷抵抗的独立危险因素。结论汉族急性缺血性脑卒中患者中,CYP2C19慢代谢基因型(*2/*2、*2/*3)和低密度脂蛋白水平升高是导致氯吡格雷抵抗的独立危险因素。 Objective To analyze the relationship between CYP 2C19 gene polymorphism and clopidogrel resistance in acute ischemic stroke patients .Methods From July 2012 to September 2014 , 72 consecutive patients with acute ischemic stroke (75 mg/d, continuous 〉7 d) who were hospitalized and treated with clopidogrel .According to the inhibition rate of platelet aggregation induced by ADP , they were divided into clopidogrel resistance (CR) group (27 cases) and non-resistant (NCR) group (45 cases).Gene chip method was used to detect the CYP 2C19 genotype of the subjects .According to the type of mutations, the gene chip was divided into fast metabolic type (*1/*1), intermediate metabolism (*1/*2,*1/*3) and slow metabolism (*2/*2,*2/*3,*3/*3).The risk factors associated with the occurrence of clopidogrel resistance were analyzed by multiple Logistic regression analysis .Results The CYP2C19 genotype distribution were statistically signifi-cant different between the two groups (χ2 =32.302, P 〈0.05);detected CYP2C19 genotypes were slow metabolism in 7 ca-ses (9.7%), intermediate metabolic genotype 39 cases (54.2%), fast metabolism type in 26 cases (36.1%), 3 groups of platelet aggregation inhibition rate respectively were (67.5 ±21.6)%, (57.6 ±23.4)%and (31.4 ±15.1)%, slow metab-olism type 〉intermediate metabolizers 〉metabotropic ( P 〈0.01).Multivariate logistic regression analysis showed that CYP2C19 slow metabolizers (*2 /*2,*2/*3) (OR=7.802, 95%CI 1.412 to 40.304, P =0.018) and low density lipid protein levels 〉2.6 mmol /L (OR=3.923, 95%CI 1.314 to 17.927, P =0.032) was independent risk factors for&amp;nbsp;clopidogrel resistance .Conclusion In patients with acute ischemic stroke , CYP2C19 (*2/*2,*2/*3) and low density lipoprotein levels were the independent risk factors for clopidogrel resistance .
出处 《疑难病杂志》 CAS 2015年第10期1013-1016,1016,共4页 Chinese Journal of Difficult and Complicated Cases
基金 陕西省科学技术发展计划资助项目(No.2014K11-02-03)
关键词 CYP2C19基因多态性 氯吡格雷 抵抗 多因素分析 CYP2C19 gene polymorphism Clopidogrel Resistance Multivariate analysis
  • 相关文献

参考文献17

二级参考文献106

共引文献2551

同被引文献84

  • 1邢东亮,宋东奎,张莉蓉.膀胱癌患者细胞色素氧化酶P450 2C19基因多态性分析[J].郑州大学学报(医学版),2006,41(2):285-287. 被引量:4
  • 2脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996,29(6):381-383. 被引量:15736
  • 3郑露,邵建国.CYP2C19基因多态性在消化系统中的意义[J].国际消化病杂志,2007,27(6):455-457. 被引量:7
  • 4JNEID H,ANDERSON J L,WRIGHT R S,et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update) a report of the American college of cardiology foundation/American heart as- sociation task force on practice guidelines developed in collaboration with the American college of emergency physicians, society for cardi- ovascular angiography and interventions, and society of thoracic sur- geons [ J 3. Circulation, 2012,126 ( 7 ) : 875. 被引量:1
  • 5CHEN Z M, JIANG L X, CHEN Y P, et al. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: random- ised placebo-controlled trial [ J I. Lancet, 2005,366 ( 9497 ): 1607- 1621. 被引量:1
  • 6YAMAMOTO K, I-IOKIMOTO S, CHITOSE T, et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy[ J]. J Cardiol, 2011,57(2) :194-201. 被引量:1
  • 7TABATA N, HOKIMOTO S,AKASAKA T, et al. Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunc- tion are significantly correlated with adverse cardiovascular events fol- lowing coronary stem implantation [ J ]. J Cardio1,2015 ( 15 ) :95-97. 被引量:1
  • 8NOZARI Y, VOSOOGHI S, BOROUMAND M, et al. The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study[J]. Anatolian Journal of Cardiolo- gy ,2015,15 ( 5 ) :348-353. 被引量:1
  • 9MATHEWKUTTY S, MCGUIRE D K. Platelet perturbations in diabe- tes: implications for cardiovascular disease risk and treatment [ J ]. Expert Rev Cardiovasc Ther, 2009,7 ( 5 ) :541-549. 被引量:1
  • 10MARIN F, ROLD6JN V, GONZ6LEZ-CONEJERO R, et al. Pharmaco- genetics in cardiovascular antithrombotic therapy [ J ]. Curr Med Chem Cardiovasc Hematol Agents,2005,3(4) :357-364. 被引量:1

引证文献7

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部